| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10343 | Diquafosol tetrasodium Featured | Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease. |
|
| DC23302 | Disarib Featured | Disarib is a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain, demonstrates strong affinity to BCL2, but not to other antiapoptotic BCL2 family members(BCL-xL, BCL2A1 etc.). |
|
| DC22511 | Disitertide | Disitertide (P144) is a TGF-β1 antagonist peptide. |
|
| DC23122 | DiZPK Featured | DiZPK is a genetically encoded, highly efficient photocrosslinking amino acid valuable in unveiling the physiological interaction partners of given proteins and their functions.. |
|
| DC22216 | DJ4 Featured | DJ4 (ROCK inhibitor DJ4) is a potent, selective, ATP-competitive inhibitor of ROCK1/2 and MRCKα/β with IC50 of 5/50 nM and 10/100 nM, respectively. |
|
| DC12431 | DKFZ-251 | DKFZ-251 (DKFZ251) is a selective inhibitor of Kallikrein-related peptidase 6 (KLK6) with IC50 of 0.13 uM, demonstrates good selectivity for KLK6 compared to other KLKs. |
|
| DC12404 | DKFZ-633 | DKFZ-633 (DKFZ633) is a selective inhibitor of Kallikrein-related peptidase 6 (KLK6) with IC50 of 0.25 uM, demonstrates good selectivity for KLK6 compared to other KLKs. |
|
| DC11025 | DKM 3-42 | DKM 3-42 is a selective, covalent, in vivo-active ALDH3A1 inhibitor with IC50 of 50 uM against purified human ALDH3A1, targets ALDH3A1 catalytic cysteine, impairs both in situ and in vivo lung cancer pathogenicity. |
|
| DC20363 | DL-AP4 sodium salt | DL-AP4 sodium salt is a broad spectrum glutamate receptor antagonist.. |
|
| DC8539 | DM1-SMCC Featured | DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate. |
|
| DC9434 | DMP 777 | DMP 777(L-694458) is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor. |
|
| DC20600 | DM-PIT-1 Featured | DM-PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain, PIP3/PDK1 PH domain, and PIP3/GRP1 PH domain with IC50 of 27.1 uM, 80.5 uM, and 35.5 uM, respectively. |
|
| DC12079 | DMU2105 | DMU2105 is a potent and specific CYP1B1 inhibitor, with IC50s of 10, 742 nM for CYP1B1 and CYP1A1, respectively. |
|
| DC7404 | DMXAA Featured | DMXAA (Vadimezan) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively. Phase 3. |
|
| DC20959 | DNDI-8219 | DNDI-8219 is a novel potent, orally active antileishmanial agent with IC50 of 0.19 uM against Leishmania donovani (L. don). |
|
| DC23671 | DNMDP | DNMDP is a potent and selective cancer cell cytotoxic agent that binds to PDE3A, promotes an interaction between PDE3A and Schlafen 12 (SLFN12). |
|
| DC11337 | MMP Substrate II Control | Dnp-GPLG is a peptide for use as a negative control for activity of matrix metalloproteinases (MMPs) that cleave peptides containing the sequence Dnp-GPLG. |
|
| DC11342 | MMP-1 Fluorogenic Substrate III | Dnp-P-Cha-Abu-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9. |
|
| DC11348 | MMP-1/MMP-9 Fluorogenic Substrate Featured | Dnp-P-Cha-G-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9 |
|
| DC11351 | MMP-1 Fluorogenic Substrate I Featured | Dnp-PLALWAR is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-8. |
|
| DC11339 | MMP-8/MMP-26 Fluorogenic Substrate Featured | Dnp-PLAYWAR is a fluorogenic substrate for matrix metalloproteinase-8 (MMP-8) and MMP-26.The activity of MMP-8 and MMP-26 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitro |
|
| DC11347 | MMP-1 Substrate II Featured | Dnp-PLG-Cys(Me)-HA-DArg-NH2 is a peptide substrate for matrix metalloproteinase-1 (MMP-1).It has an improved kcat/Km ratio compared with the MMP-1 flurogenic substrate Dnp-PLGLWA-DArg-NH2. |
.png)
|
| DC11344 | MMP-2/MMP-9 Fluorogenic Substrate I | Dnp-PLGMWSR is a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-9.The activity of MMP-2 and MMP-9 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitroph |
|
| DC11345 | MMP-7 Fluorogenic Substrate | Dnp-RPLALWRS is a fluorogenic substrate for matrix metalloproteinase-7 (MMP-7).The activity of MMP-7 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitrophenol (Dnp) group. |
|
| DC21509 | DNS-pE | DNS-pE (PHGDH Fluorescent Probe DNS-pE) is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
| DC20364 | DNS-pE2 | DNS-pE2 is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
| DC20136 | DO34 analog | DO34 analog is a triazole DAGL(α) inhibitor extracted from patent WO2017096315 A1, compound 100. |
|
| DC20960 | DO-34 | DO-34 is a highly potent dual DAGLα/β inhibitor with IC50 of 6 nM 3-8 nM, respectively. |
|
| DC8416 | Docetaxel Trihydrate | Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules. |
|
| DC4187 | Docetaxel Featured | Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules through binding to stabilized microtubules. |
|
